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Efficacy of the treatment was similar for imipenem and meropenem (79%
and 81 %). Mortality rate in both groups (18%) was closely related to clinical
disease and was higher (about 45%) in septic complications of acute
pancreatitis and pneumonia with ARI. Our clinical experience with carba-
penems confirmed their value in empiric therapy of septic surgical compli-
cations.
but have not yet reached 112 weeks of follow-up. Significantly fewer
patients in the EFV + ZDV + 3TC arm required discontinuation for
adverse events (P ::; .05).
Conclusions: The combination of EFV + ZDV + 3TC continues to
demonstrate superior efficacy, durability and tolerability over IDV +
ZDV + 3TC in patients treated over a prolonged period of time.
CD4 < 100 CD4 ~ 100 CD4 < 100 CD4 ~ 100
EFV + ZDV + 3TC 67.5%* 69.4%* 55.0% 63.9%*
(27/40) (202/291) (22/40) (188f294)
EFV + mv 34.2% 58.0%t 23.1% 53.0%t
(13/38) (171/295) (9/39) (157f296)
IDV + ZDV + 3TC 45% 49.2% 35.0% 44.3%
(18/40) (152/309) (14/40) (139/314)
* p < 0.05 EFV + ZOV + 3TC v, IOV + ZOV + 3TC: t p < 0.5 F.FV + mv
vs mv + ZDV + 3TC
Condusions: Patients with baseline CD4 counts < 100 cells/mm3 treated
with EFV + ZDV + 3TC demonstrated similar response rates through 48
weeks as those with higher baseline CD4 counts. EFV + ZDV + 3TC
maintained its superiority over IDV + ZDV + 3TC even in patients with
low CD4 counts at baseline.
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IWeP253I Successful virologic suppression with Efavirenz in
HIV-infected patients with low baseline CD4 cell counts: Post hoc
results from Study 006
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P. PalterS, F. Milazz06,]. L. Touraine7, T. O. Saint Marc7, D. R. Farina8,
L.). 8essen8, N. M. Ruiz8
Study 006 Team; 1St. Stephen's Centre, London, United Kingdom; 2Klinikum
derJ. W. Goethe-Universitat, Frankfurt, Germany; JClin. Res. Puerto Rico,
Inc., Sanjuan, PR, United States; <Hospital de Mos/oles, Madrid; 5Cuidad
Sanitaxia de Bel/vitge, Barcelona, Spain; 6Luigi Sacco Hospital, Milan, Italy;
7Hospital Edouard-Herriot, Lyon, France; 8DuPont Pharma. Co., Wilmington,
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Background: Efavirenz (EFV, SUSTIVA18) with NRTis demonstrates
similar response rates in patients with baseline viral loads above and below
100,000 copies/mi. The objective of this analysis is to explore the antiviral
activity and efficacy of EFV in therapy-naIve patients with baseline CD4
counts < 100 cells/mm3.
Methods: Post hoc analysis ofStudy 006, N = 1266 PI, NNRTI-and 3TC-
naive patients. Baseline characteristics for patients with CD4 < 100 cells/
mm3: male-84%; caucasian-60%; mean age-39.3 (±8.7); mean HIV-1
RNA (VL)-5.32 log10 copies/mL (epm) (208,930 epm); mean CD4- 63.6
cells/mm3.
Results: (NC = F):
IWeP254IOral oseltamivir is effective in the treatment of
acute influenza in a vaccinated population
M. Zaug1, P. Mahoney2, P. Ward2
On behalfoj the Osrltamivir Study Group; 'F. Hoffmann-La Roche, Base/,
Switzerland; 2Roche, Welwyn, United Kingdom
Objective: Oseltamivir, the oral prodrug of the neuraminidase inhibitor
GS4071, has previously demonstrated efficacy in treatment ofacute influenza
in otherwise healthy unvaccinated patients. Elderly or patients with chronic
cardiac/respiratory disease are considered to be at risk for significant
morbidity and mortality associated with influenza infection. However,
vaccination does not provide complete protection and vaccinated patients
may still develop influenza illness. Thw there is need for an effective antiviral
treatment for the vaccinated population. We evaluated the benefits of
oseltamivir in the treatment of influenza in a vaccinated 'at risk' population
including the elderly and patients with chronic cardiac/respiratory disease
(aged> 13).
Methods: Vaccinated patients presenting with acute febrile influenza illness
< 36 h after onset of symptoms received oseltamivir 75 mg bid or placebo
for 5 days. Symptoms were scored twice daily on a diary card (0 = absent, 1
= mild, 2 = moderate, or 3 = severe). The endpoint was the time to
-
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IWeP251I Probiotic supplementation during administration of
cefpodoxime proxetil
K. Orrbage1, S. Sjostedt2, C. E. Nordl
,Departments ofMicrobiology, Pathology and Immunology; 2Surgery, Huddinge
University Hospital, Karolinska Institutet, Stockholm, Sweden
Objectives: To study the intestinal microflora and clinical status in healthy
volunteers during administration of cefpodoxime proxetil with or without
supplements of Bifidobaclerium longum and Lutobacillus acidophilus and
oligofructose.
Methods: Three groups ofhealthy volunteers with 10 persons each received
cefpodoxime proxetil perorally bid for 7 days. One of the groups also
received a fermented milk product with 1011 CFU of B. Iongum BB 536 and
L. acidophilus NCFB 1748 and IS g oligofructose daily, another group had
only oligofructose and the last group received a placebo product, for 21 days.
Fecal samples were collected for microbiological analyses and clinical status
of volunteers was recorded.
Results: In the lactic acid bacteria administered group Clostridium d!fficile
was found in only one person at one sampling occasion, whereas in the other
two groups six persons each became colonized. In the rest of the anaerobic
microflora there was a dramatic decrease in microorganisms on the 4th day
of administration, mainly due to a loss of bifidobaeteria in all groups. The
administered strain of bifidobacteria was recovered in one volunteer. The
number of lactobacilli also decreased but the administered strain of L.
acidophilus was identified in six persons. The treatment was well tolerated
by the volunteers and did not cause any serious side effects.
Conclusions: The administration of the two probiotic microorganisms,
capable of surviving the passage through the intestinal tract, may have
influenced the ecology of the intestinal microflora thereby decreasing the
colonization of C. difficile.
K. Tashima l , S. Staszewski2,). O. Morales-Ramirez3, A. Rachlis·, R.
StrykerS, D. R. Farina6, D.). Manion6, N. M. Ruiz6
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Objective: Study 006 demonstrated superior efficacy and tolerability of
efavirenz(SUSTIVAt8) + ZDV + 3TCoverlndinavir(IDV) + ZDV +
3TC at 72 weeks.
Methods: Randomized study of PI-, NNRTI- and 3TC-nalve patients;
mean HIV-1 RNA (VL)-60.256 copies/mL (epm); mean CD4 count-341
cells/mm3. KM: pts never reaching < 400 cpm assigned zero days for DOR,
otherwise DOR equal to time to VL > 400 cpm, discontinuation from
study or AIDS-defining illness.
Duration ofResponse:
P:8/3 - dinical trials of antimicrobial agents - III
IWeP252I Continued viral suppression in patients treated
with efavirenz (EFV) + zidovudine (ZDV) + lamivudine (3TC) at
112 weeks: Kaplan-Meier analyses for the extended cohort of
study 006 (n = 1266)
This analysis allows for the inclusion of data beyond 48 weeks as Kaplan-
Meier estimates by accounting for patients who are still virologic responders
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alleviation ofsymptoms (score of0 or 1 and remaining so for a minimum of
24 h).
Results: 140 vaccinated patients with confirmed influenza were evaluated.
The median duration of illness was reduced by 1.8 days in the oseltamivir
recipients (n = 64) compared to placebo (n = 76) (oseltamivir: 6.4 d,
placebo: 8.2 d). These results show a clinically relevant benefit in the
treatment of acute influenza in the vaccinated population.
Conclusion: This study showed that treatment with oral oseltarnivir pro-
vides an additional benefit for the vaccinated patients who develop influenza
despite the fact that they are vaccinated.
IWeP255I Relief of cytokine mediated symptoms with oral
oseltamlvlr treatment of influenza infection
S. L.Johnstonl, P. Mahonel, P. Ward2
'NHLI at St Mary's, London; 2R o<he, Welwyn, United Kingdom
ObJective: Recent evidence suggests a link between virus replication,
cytokine elaboration. and symptom production during acute influenza
(Hayden, JAMA 99; 282:1240). Cytokine-mediated symptoms (fever,
myalgia, chills) are the most burdensome for patients with influenza. The
efficacy of oral oseltamivir in reducing the time to alleviation of cytokine
mediated influenza symptoms (fever, myalgia and chills) in 'at risk' patients
(elderly patients or those with chronic cardiac or respiratory illness (COAD)
was srudied).
Methods: Patients with acute febrile influenza illness < 36 h after symptom
onset received oral oseltamivir 75 mg bid or placebo for 5 days. Symptoms
were scored twice daily on a diary card (0 = absent. 1 = mild. 2 =
moderate, or 3 = severe). The endpoint was the time taken to become
afebrile (temperature < 37.2°C) and a score of0 or 1 for myalgia or chills
that remained so for a minimum of24 h. All patients were given paracetamol
to take ad libirum.
Results: A total of 322 'at risk' patients were enrolled (mean age 60.6,
COAD 45.3%, elderly 52.3%) suffering from acute influenza. The total
duration ofcytokinc-mediated symptoms was significantly reduced by 36%
in oseltamivir (median 37 h. p < 0.0001) compared with placebo (median 58
h). The use of paracetamol was lower in the oseltamivir group.
Conclusion: In the 'at risk' population oral oseltamivir significantly reduces
the impact ofcytokine-mediated symptoms fever, chills and myalgia during
the most uncomfortable period of influenza illness.
IWeP256 t Oral oseltamivir for prevention of influenza in the
frail elderly
V. De Bockl • P. Peters2• T. von Planta3, M. Gibbens\ P. Ward3
'Eeuwfeestkliniek, Antw"pen, Belgium; 2Leon Valley Diagnostic Clinic, San
Antonio, Texas, United States; JRoche Global Development, Basel,
Switzerland; Welwyn, United Kingdom
Objective: Influenza illness is an important cause of severe morbidity and
mortality in the elderly population. This multicenter, double-blind. pla-
cebo-controlled study assessed the efficacy and safety of oral oseltamivir for
prevention ofnarurally acquired influenza in a residential home population.
Methods: The frail elderly population (548 subjects, 65-96 yrs, median age
82 years) included 80.3% who were vaccinated prior to the influenza season.
98% with co-morbid conditions including cardiac, respiratory and gastro-
intestinal diseases and 98% taking concomitant medications. Subjects
received oseltamivir 75 mg or placebo once daily for six weeks during a
period oflocal influenza activity and were assessed for influenza at baseline,
weeks 3, 6 and 8. and at any time they experienced influenza-like symptoms.
Results: The proportion of patients with laboratory confirmed clinical
influenza illness (primary efficacy parameter, defined as temp ~ 99°F, ~1
respiratory and ~1 constitutional symptom) was 4.4% (12/272) for placebo
and 0.4% (1/276) for oseltamivir recipients. The overall protective efficacy
was 92% (p = 0.0015). Despite a good match of vaccine with circulating
influenza virus strains during the season, 12 ofthe 13 influenza cases occurred
in vaccinated patients. The low number of reported adverse events were
similar between the placebo and oseltamivir treatment groups. Upper
gastrointestinal events related to study treatment were reported by 15
(5.5%) placebo recipients and 17 (6.1 %) oseltamivir recipients.
Conclusion: Long term daily administration of oseltamivir 75 mg effec-
tively prevents influenza illness and is well tolerated by a vaccinated. frail
elderly population, most of whom were taking a variety of concomitant
medic2tions.
!WeP257! Oral oseltamivir is eective and safe In the
treatment of children with acute influenza
K. Reisingerl • F. Hayden2 , R. Whitley3, R. Dutkowski4 , D. Ipes, R.
Mills6 , P. WardS
'Primary Physicians Research, PA; 2Univ . of Virginia; JBirmingham Children's
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Sciences, CA, United States
Objective: This placebo controlled. double-blind study investigated the
efficacy and safety of a liquid formulation of oseltamivir in 698 children
(aged 1-12) with acute influenza.
Methods: Children with febrile respiratory illness < 48 h duration were
randomized to receive oseltamivir 2.0 mg/kg. or placebo bid for 5 d. The
primary endpoint was resolution of illness (cough and coryza mild/absent,
return to normal health/activity, afebrile). Other endpoints included time to
rerum to normal health/activity. duration and severity of symptoms and
secondary illnesses requiring antibiotics.
Results: 452 (65%) patients had laboratory-confinned influenza. Compared
with placebo, oseltamivir treatment reduced median time to alleviation of
illnes., in infected children by 26% (5.7 vs4.2 d; P < 0.0001). Median time to
return to normal health/activity was reduced by 40% (4.7 d vs 2.8 d; p <
0.0001). median duration ofillness by 37% (4,2 d vs 2.6 d; P < 0.0001) and
severity by 29% (1358 vs 967 score.h; p < 0.002) in placebo and oseltamivir
recipients. respectively. Compared with placebo, secondary complications
(bronchitis, pneumonia, otitis media or sinusitis) requiring antibiotics were
reduced by oseltamivir by 40% (placebo:65/235, oseltamivir:36/217; p <
0.005). In particular, oseltamivir treatment was associated with a 44%
reduction (95% CI 13-64) in the development of acute otitis media and
associated antibiotic use. Treatment with oseltamivir was well tolerated,
with low discontinuations due to adverse events in both groups (pla-
cebo:1.1 %; oseltamivir:1.8%).
Conclusion: Oral oseltamivir is the first therapy for influenza in children
aged 1-12 to reduce both illness manifestations and risk ofupper and lower
respiratory complications.
IWeP258 t Impact of oral oseltamivir treatment on symptom
the alleviation time-course for influenza
P. Mahoneyl, P. Ward l
On behalfof the Oseltamivir Study Group; I Roche Global Development,
Welwyn, United Kingdom
Objective: The novel influenza therapy oseltamivir is the oral prodrug of
GS4071, a potent influenza neuraminidase inhibitor. We evaluated the effeet
ofoseltamivir on alleviation ofinfluenza illness at 12-hour timepoints (up to
168 hours post-treatment).
Methods: A total of 605 otherwise healthy adults with narurally acquired
influenza were randomized in placebo controlled studies. Subjects received
oseltamivir 75 mg (n = 297) or placebo (n = 308) twice daily for 5 days,
starting within 36 hours of symptom onset. Subjects scored each of 7
symptoms ofinfluenza (cough, feverishness, myalgia, sore throat, headache,
nasal symptoms and fatigue) on a 4 point scale (0 = absent. 1 = mild. 2 =
moderate, 3 = severe) at baseline and twice daily for 21 days. Alleviation of
illness was defined as the time from start of medication until all symptoms
scored ~1 for a 24 h period.
Results: Oseltamivir treatment resulted in a shorter time to alleviation of
influenza symptoms compared with placebo. The proportion of subjects
with all symptoms alleviated at each timepoint post first dose was reduced
following oseltamivir treatment compared with placebo. The beneficial
effect with oseltamivir started within 24 hours of start of treatment, with
45% more patients reporting symptom alleviation with oseltamivir at 24
hours than placebo. This increased to 50% after 36 hours of treatment.
Conduslon: Treatment of influenza with oral oseltamivir 75 mg bid for 5
days halves the proportion of patients reporting influenza symptoms at 36
hours post treatment. The beneficial effect of oseltamivir starts within 24
hours of administration.
~~ Soluble receptors for tumor necrosis factor (sTNFR)
in visceral leishmaniasis treated with amphotericin B lipid
complex
A. Liberti. L. Loiacono, G. De Luca, S. Vigano1
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Introduction: Patients with Visceral Leishmaniasis (VL) show elevated
serum concentrations of TNT that decrease after effective treatment. The
soluble TNT receptors (sTNFR), types I and II, may play an important role
in regulating the bioavailability of TNF.
The potential use ofserum sTNFR levels as markers ofdisease activity in
patients with VL and as parameters for monitoring the efficacy of Ampho-
tericin B Lipid Complex Therapy was assessed.
Eleven patients with active VL that was confirmed by bone marrow,
lymphonode, or splenic aspiration received treatment that consisted of
Amphotericin B Lipid Complex.
The serum concentrations of TNF and sTNFR were determined before
and after Therapy.
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!Tu01! Trypanosoma bruce; bnJcei induces interferon-r
expression in rat dorsal root ganglia cells via a tyrosine kinase
dependent pathway
Moiz Bakhiet, Ahmed Sharafeldin, Ragaa Eltayeb
Division ofInfectious Diseases, Karolimka Institute, Huddinge University
Hospital, Stockholm, Sweden
Dorsal root ganglia (DRG) were shown to express neuronal IFN--r that
supports Trypanosoma brucei brucei growth. Herein. the ability ofa trypano-
some-derived factor (TLTF) to activate DRG to neuronal IFN--r secretion
was investigated together with the signalling pathway that might be
involved during this process. Immunohistochemical staining revealed
expression of neuronal IFN-1' upon stimulation with TLTF, which was
blocked with the tyrosine protein kinase (TPK) inhibitor tyrphostin (A47).
Western blot was used to analyze DRG Iysates prepared at different time
points after stimulation with TLTF. A tyrosine-phosphorylated protein
induced at 15 minutes was seen as a band of 120-150 kD, followed by a
decrease to control levels after 30 minutes. A47 has greatly suppressed the
TLTF-induced protein tyrosine kinase activity. In addition. evidence sug-
gesting that the transcription factor STAT-I may playa key role in TLTF
signalling pathway is presented as shown by A 47 blocking effects ofSTAT-
I translocation to the nucleus.
ITu0211n experimental pneumococcal meningitis the free
radical scavenger a-phenyl-tert-butyl-nitrone increases
apoptosls In the hippocampus and impairs learning capacity
J. Looffler. R. Ringer, M. G. Tauber, S. L. Leib
Inst.for Med. Microbiol., Univ. ofBern, Bern, Switzaland
Objectives: To evaluate in experimental pneumococcal meningltJs, the
effect of the radical scavenger a-phenyl-tert-butyl-nitrone (PBN) on
cortical necrosis and hippocampal apoptosis by histopathology and on
learning capacity by the Morris Water Maze task.
Methods: Eleven day old rats were infected intracisternally with 10 J.tl of
saline containing 10glO 6.39 ± 0.14 cfu/ml Streptococcus pneumoniae and
randomized for treatment with PBN (100 mglkg i.p. q8h, n = 44) or saline
(250 J.tl i.p. q8h, n = 46), starting at the time of infection. Vninfected
controls were sham inoculated with 10 JlI of saline (n = 26). All infected
animals were treated with ceftriaxone (100 mg/kg s.c. bid) starting at 18 h
after infection. For histopathology, animals (PBN, n = 18; saline, n = 18;
controls, n = 4) were evaluated at 21.8 ± 2.0 h after infection. Animals to be
studied by the water maze task (PBN, n = 20; saline, n = 23). were treated
for 4 days, and learning capacity compared to uninfected controls (n = 22)
was assessed at 3 weeks after cured infection.
Results: Cortical injury was reduced by PBN, compared to saline (median
[rangeJ 0% [0-3O.9J% vs 3.97% [0-38.9%J, p < 0.001). In contrast,
apoptosis in the hippocampal dentate gyms was increased by PBN (1.15
[0.04-1.73] vs 0.31 [0-0.92], P < 0.0001). Compared to uninfeeted controls,
animals surviving pneumococcal meningitis showed decreased learning
capacity (p < 0.0001) which was even was further impaired by PBN (p
< 0.03), compared to saline.
Conduslons: PBN, which reduced cortical injury and hippocampal apop-
tosis in experimental group B streptococcal meningitis, aggravated hippo-
Results and Conduslons: All patients showed significant elevations of
sTNFR. All patients had an initial response to treatment and serum
concentrations of sTNFR declined to levels similar to those of normal
controls.
In the two responders who had subsequent relapses, sTNFR concentra-
tions increased at the time ofthe relapses. Only 20% (two) ofthe patients had
detectable TNF in serum.
Measurement ofserum sTNFR concentrations may provide a useful way
of monitoring the effectiveness of treatment for VL.
With further study, sequential measurements ofsTNFR may be able to
replace repeated aspiration of bone marrow, spleen or lymphonodes in
monitoring The Treatment of VL.
campal damage and in consequence impaired learning capacity in the present
model of pneumococcal meningitis. Antioxidant therapy in experimental
meninigitis is not uniformly beneficial.
ITu03IRelease of DNA from Stteptoeo«us pneumonlae
during spontaneous growth and antibiotic treatment
J. Gerber', H. Eiffert2, H. Fleischer!, A. Wellmerl , V. Munze13, R. Nau2
I Depts. ofNeurology; 2Medical Microbiology; JBiomathematics and Medical
Statistics; University of Gottingen, Germany
Objective: To study the release ofDNA from Streptococcus pneumoniae in
vitro during spontaneous growth and treatment with ceftriaxone and
rifampin by a newly developed semi-quantitative polymerase chain reaction
method.
Methods: A S. pneumoniae type 3 strain was suspended in fresh tryptic soy
broth to a final concentration of6.9 ± 0.24 10gCFUIml at 37"C. Ceftriax-
one or rifampin were added at a concentration of 10 mg/l. Control group
received no antibiotic (n = 6 each group). Bacterial counts were determined
at 0, 3, 6, 9, and 12 h. Samples for the detection of released bacterial DNA
were collected hourly, centrifiIgated and the supematans were frozen at
-200 e. Bacterial DNA was separated from the supernatant (phenol extrac-
tion), precipitated with 100% ethanol and 3 M sodium acetate and
centrifugated. Pellet was resuspended in I x PSR buffer and the solution
was serially diluted I:10. Equal amounts ofthe four desoxynucleotidetripho-
sphates, Taq DNA polymerase and broad-range PCR primen for the
detection of the 16S rRNA gene of bacteria were added. PCR products
were visualized on agarose gel electrophoresis. The highest dilution of the
original sample, from which a PCR product could be amplified, was defined
as the number of units (V) per mi in the original sample. 1 V/ml was the
equivalent of approximately 600 CFV/ml.
Results: An intense release ofDNA occurred in untreated cultures. The area
under concentration-time curve (AVC) ranged from 63,700 to 3,398,100 V
x hlml (median = 1,572,550 V x h/ml).ln each individual experiment, the
AVCs of untreated S. pneumoniae were 2.3-46 fold (median = 19 fold)
higher than those ofceftriaxone-treated cultures (27,900-147,000 V x hlml,
median = 88400 V x h/ml, p = 0.03 versus untreated controls). Rifampin
released the lowest quantities of DNA, the AVCs of S. pneumoniae cultures
treated with ceftriaxone being 1.2-2.8 fold (median = 2.7 fold) higher than
those of rifampin-treated cultures (16,500-101,000 V x h/ml, median =
32200 V x blml, p = 0.03 versus ceftriaxone).
Conclusions: Rifampin decreases not only the release of lipoteichoic acid
but also of DNA from S. pneumoniae in comparison with ceftriaxone and
may therefore reduce the inflammatory burst observed at the onset ofacute
infection.
ITu041 Anti CD14-dependent Inhibition of TNF release from
mononudear cells stimulated by peptidoglycan components
P. Majcherczyk, P. Moreillon, M. Glauser, D. Heumann
Division of Infectious Diseases, CHUV, Lausanne, SWitzaland
Introduction It Objectives: LPS induces cytokine production from respon-
sive cells such as peripheral blood mononuclear cells (PBMCs). This is
mediated by binding to the cell surface receptor CD14. The peptidoglycan
(PG) component ofGram-positive bacteria also induces cytokine release, but
the role ofCD14 is equivocal. Comparison ofprevious studies is complicated
